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Abstract
The IFNL3 (IL28B) gene has received immense attention in the hepatitis C virus (HCV) field as
multiple independent genome-wide association studies identified a strong association between
polymorphisms near the IFNL3 gene and HCV clearance. However, the mechanism underlying
this association has remained elusive. In this study, we report the identification of a functional
polymorphism (rs4803217) located in the 3′ untranslated region (3′ UTR) of the IFNL3 mRNA
that dictates transcript stability. This polymorphism influences AU-rich element-mediated decay
as well as the binding of HCV-induced microRNAs during infection. Together, these pathways
mediate robust repression of the unfavorable IFNL3 genotype. These data reveal a novel
mechanism by which HCV attenuates the antiviral response and uncover new potential therapeutic
targets for HCV treatment.
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tHepatitis C virus (HCV) infects over 150 million people worldwide. Treatment for chronic
HCV infection is based on interferon (IFN) combination therapy with ribavirin. A newly
approved triple combination treatment, which includes direct-acting antiviral (DAA) agents,
has improved viral cure rates to greater than 60%1. However, emergence of therapy-resistant
HCV variants in patients treated with DAAs has become an important concern1,2. Genome-
wide association studies (GWAS) have identified three single nucleotide polymorphisms
(SNPs) near the IFNL3 (IL28B) gene that strongly associate with HCV patient response to
therapy3–6 and natural clearance of infection6,7. However, the functional polymorphism
mediating these associations is still unknown.
IFNL3 is a member of the interferon-λ (IFNL) cytokine family, which is comprised of
IFNL1 (IL-29), IFNL2 (IL-28A) and IFNL3, all of which are encoded by genes clustered on
human chromosome 198,9. IFNLs are induced in both hematopoietic and nonhematopoietic
cells by various human viruses10. Unlike IFN-α/β, IFNL signaling exhibits cellular
specificity as the IFNL receptor is narrowly distributed on epithelial cells, melanocytes and
hepatocytes, suggesting that IFNLs represent a family of cytokines that evolved to
specifically protect epithelia from viral invasion11. IFNLs are potent antiviral cytokines that
have the ability to inhibit HCV replication, and when paired with DAAs have shown
comparable antiviral activity against HCV to IFN-α12,13. IFNL and IFN-α induce a similar
repertoire of IFN-stimulated genes (ISG) in human hepatocytes, although treatment with
IFNL induces a steady increase in expression instead of the rapid peak and decline seen with
IFN-α12,14. Several confounding studies have shown that the IFNL3 unfavorable genotype
associates with higher pre-therapy ISG levels during HCV infection15,16. However,
correlations between ISG levels and IFNL3 genotype have been shown to differ by cell
type16, and when treatment response (non-responders versus responders) is stratified by
IFNL3 genotype, there is no difference in total mean baseline ISG expression17. This
suggests that IFNL3 genotype and pre-therapy ISG levels are independent predictors of IFN
responsiveness in chronic HCV patients17.
While five studies have found a correlation between IFNL3 genotype and IFNL3
expression3,4,18–20, where higher IFNL3 levels associate with clearance, three studies found
no association5,15,21. One study which demonstrated an association in normal liver also
found that individuals with the favorable IFNL3 genotype expressed the highest levels of
ISGs19. As discussed, this is opposite to what has been found in baseline gene expression
analyses of chronic HCV patients, suggesting that chronic infection dysregulates the
immune response making correlations between IFNL3 genotype and gene expression less
straightforward. Furthermore, cytokine mRNAs are extremely labile in nature, making them
very difficult to measure in biological samples. As there are substantial data supporting a
correlation between IFNL3 genotype and IFNL3 expression, we set out to determine
whether there is a functional variant that mediates expression differences of this cytokine.
Four candidate causal SNPs have been identified that are in linkage disequilibrium with the
GWAS SNPs22–24. None of these candidate SNPs, which are located in the IFNL3 promoter,
intron, coding region or 3′ untranslated region (UTR), have been previously shown to
functionally affect IFNL3 expression. As cytokine gene expression is under tight post-
transcriptional control25, we hypothesized that variation in the IFNL3 3′ UTR (SNP
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trs4803217) might alter mRNA turnover and protein expression by interfering with
regulatory elements. The frequency of the rs4803217 T variant (unfavorable genotype) is
more common amongst African populations (T=55%, G=45%) and least common in Asians
(T=7%. G=93%) (www.1000genomes.org). A similar frequency is seen for the GWAS tag
SNP rs12979860, which is in linkage disequilibrium with the 3′ UTR SNP. The differences
in frequency between populations has been proposed as the reason why individuals of
African descent are less likely to clear HCV than Asians, as the unfavorable genotype is
more frequent in those patients7. In this study, we show that SNP rs4803217 is responsible
for robust expression differences between clearance (G/G) and non-clearance (T/T) IFNL3
genotypes thus identifying rs4803217 as a critical functional SNP that directs HCV infection
outcome through the control of IFNL3 mRNA stability. Our data reveal HCV induction of
two microRNAs, miR-208b and miR-499a-5p, which target the polymorphic region of the
IFNL3 3′ UTR, as a novel strategy of immune evasion by HCV and propose these
microRNAs as therapeutic targets for restoring the host antiviral response.
RESULTS
Influence of 3′ UTR SNP rs4803217 on IFNL3 mRNA
We evaluated the influence of the 3′ UTR rs4803217 SNP on the post-transcriptional
regulation and stability of the IFNL3 mRNA. Full-length IFNL3 3′ UTRs containing either a
T (IFNL3-T) or G (IFNL3-G) at position 53 in the 3′ UTR were cloned downstream of the
luciferase gene in a pGL3 reporter construct (Fig. 1a and Supplementary Fig. 1a, b) and
luciferase activity was measured in transfected human hepatoma (HepG2 and Huh7) cells.
The IFNL3-T 3′ UTR conferred 30–40% lower luciferase activity compared to the IFNL3-G
3′ UTR (Fig. 1b). We next assessed the effect of rs4803217 on mRNA stability. Analysis of
firefly luciferase mRNA levels remaining in HepG2 cells post-Actinomycin D treatment
revealed that luciferase mRNA bearing the IFNL3-T 3′ UTR decayed twice as fast compared
to the IFNL3-G 3′ UTR, demonstrating that this single nucleotide change affected the
general stability of the mRNA transcript (Fig. 1c). Taken together, these data show that
rs4803217 strongly influences the stability and expression of IFNL3.
Like many cytokines, the IFNL3 3′ UTR contains cis-acting repetitive adenosine-uridine
stretches or AU-rich elements (ARE) (positions 33–37, 58–62 and 79–83; Fig. 1d and
Supplementary Fig. 1a). AREs are perhaps the best-known determinants of mRNA stability
as degradative RNA-binding proteins can bind to AREs leading to ARE-mediated decay
(AMD) of the transcript26. IFNL3 can be categorized as a class I ARE-containing mRNA, as
it has 3 copies of the pentameric motif AUUUA. We generated IFNL3 3′ UTR luciferase
reporter constructs with disrupted ARE motifs (Fig. 1d; ΔARE, AUUUA→AUCUA) and
measured luciferase expression in transfected HepG2 cells. Both the IFNL3-T ΔARE and
IFNL3-G ΔARE 3′ UTRs were completely protected from repression, showing equivalent
rescue over the IFNL3-T and IFNL3-G 3′ UTRs (Fig. 1e). These data demonstrate that the
AREs in the IFNL3 3′ UTR are functional and facilitate AMD of this cytokine.
The expression differences between IFNL3-T and G were not maintained in the absence of
AMD, suggesting that AMD may have a stronger impact on IFNL3-T stability. To explore
this further, we generated luciferase reporter constructs with individual ARE sites (1–3)
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tdisrupted in both the IFNL3-T and IFNL3-G 3′ UTRs. We observed that the differential
regulation of IFNL3-T versus G was only maintained in the presence of both ARE 1 and
ARE 2 and did not require activity at ARE 3 (Fig. 1f). However, when ARE 1 or ARE 2
were disrupted individually, the difference in degradation between the IFNL3-T and IFNL3-
G 3′ UTRs was not significant. This suggested that ARE 3 participated in equal degradation
of both variants, whereas the combined activity of AREs 1 and 2 facilitated differential
AMD. It is possible that the location of rs4803217 between ARE 1 and ARE 2 alters the
local secondary structure of the mRNA thereby disrupting the ability of ARE-binding
proteins to effectively degrade the IFNL3-T mRNA. Comparisons between predicted base
pair probabilities of IFNL3-T versus IFNL3-G 3′ UTRs showed that the only sites with
significant differences between the 3′ UTR variants were ARE 1, ARE 2 and the rs4803217
SNP (Supplementary Fig. 1c). Structural changes in motif-defining sequences, such as
AREs, within the 3′ UTR can have functional consequences by influencing accessibility to
trans-acting RNA decay factors27.
The IFNL2 and IFNL3 cytokines have 98% amino acid sequence similarity8,9 and 95% 3′
UTR sequence identity (Supplementary Fig. 1a). In contrast, the 3′ UTRs of IFNL3 and
IFNL1 have a low sequence identity (47%) but do share conservation within the AREs
(Supplementary Fig. 2a). The IFNL3 3′ UTR T variant of rs4803217 is the ancestral allele
and only in humans has a G variant emerged (Supplementary Fig. 2b). Interestingly, there
are no known IFNL2 variants that associate with HCV clearance. In contrast to type I and
type II IFNs, the IFNL members have been strongly affected by positive selection28. This
previous analysis revealed that five SNPs near or in the IFNL3 gene, including rs4803217,
have rapidly increased in frequency. However, position 53 (which aligns with rs4803217 in
the IFNL3 3′ UTR) is fixed in the 3′ UTR of IFNL2 with a T nucleotide. To understand why
the polymorphism at this site was evolutionary selected for in IFNL3 and not IFNL2, we
cloned into luciferase reporter constructs the full-length IFNL2 3′ UTR as well as one in
which the native T nucleotide at position 53 was replaced with a G (IFNL2 T→G)
(Supplementary Fig. 2c). When expressed in HepG2 cells, the luciferase activity of the
IFNL2 wild type T 3′ UTR construct was significantly higher (+15%) than IFNL3-T (Fig.
1g). The IFNL2 T→G 3′ UTR resulted in only a small increase in luciferase activity
compared to the expression of the wild type 3′ UTR. We also investigated whether a ΔARE
IFNL2 3′ UTR would rescue the expression of the luciferase reporter and found that, like the
IFNL3 ΔARE 3′ UTRs, it was completely protected from repression (Supplementary Fig.
2d). Overall these data indicate that like IFNL3, IFNL2 mRNA is subjected to post-
transcriptional regulation by AMD but is not degraded to the same extent as IFNL3-T.
microRNA regulation of IFNL2 and IFNL3
Since a 3′ UTR variant of HLA-C is known to strongly associate with control of HIV
infection and drives high expression of HLA-C by escaping regulation by miR-14829, we
reasoned such a mechanism could operate on IFNL3. miRNAs are a class of small (~22
nucleotides) regulatory RNA molecules whose main function is to decrease protein-coding
mRNA levels by directly pairing with the target 3′ UTR mRNA30. Recent work has
demonstrated that miRNAs can cooperate with ARE-binding proteins to destabilize
cytokines31. We investigated whether the rs4803217 3′ UTR SNP, in addition to mediating
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tdifferential AMD, could influence recruitment of miRNAs to the IFNL3 3′ UTR. We
examined the 3′ UTR sequence around rs4803217 for predicted miRNA binding sites and
identified potential binding sites for hsa-miR-208b and hsa-miR-499a-5p, two miRNAs with
identical seed regions in the IFNL3-T and IFNL2 3′ UTRs (Fig. 2a and Supplementary Fig.
1a). The rs4803217 T→G SNP is in the miRNA seed region and is therefore predicted to
prevent the binding of these miRNAs to the IFNL3-G 3′ UTR.
The MIR208B and MIR499A genes are encoded within the introns of two myosin genes,
myosin heavy chain 7 (MYH7) and myosin heavy chain 7B (MYH7B), respectively (Fig. 2b).
They are part of a group of miRNAs termed ‘myomiRs’ due to their location and
coexpression with their corresponding myosin genes32. A key feature of these myomiRs is
their restricted expression to cardiac and slow skeletal muscle, as MYH7 and MYH7B encode
the major contractile proteins of muscle. In this setting, miR-208b and miR-499a-5p control
myosin expression and skeletal myofiber phenotypes by targeting transcriptional repressors
of myofiber genes32. As these miRNAs are not normally expressed in the liver and were not
detectable constitutively in HepG2 or Huh7 cells, we tested if HCV infection could induce
their expression. We found that HCV infection strongly induced expression of the myosin
genes and their myomiRs (Fig. 2c, d and Supplementary Fig. 3a). Another myomiR family
member encoded in the myosin gene MYH6, miR-208a, has a seed sequence identical to that
of miR-208b and miR-499a-5p and was predicted to target the IFNL3-T 3′ UTR, but we
could not detect its induction by HCV infection. Therefore, in this study, we set out to
characterize the effects of the HCV-inducible myomiRs, miR-208b and miR-499a-5p, on the
3′ UTRs of IFNL2 and IFNL3.
We co-transfected HepG2 cells with miR-208b, miR-499a-5p or negative control mimics
and luciferase reporter constructs containing the IFNL3-T, IFNL3-G or IFNL2 3′ UTR. Both
miR-208b and miR-499a-5p significantly reduced the luciferase activity of the IFNL3-T 3′
UTR but not the IFNL3-G 3′ UTR compared to the negative control (Fig. 2e). To test
whether ARE-binding proteins are involved in the recruitment of the miRNA-induced
silencing complex (miRISC) to the IFNL3 3′ UTR, we co-transfected the myomiR mimics
with the IFNL3 ΔARE luciferase reporter constructs. Similar to results obtained with the
IFNL3-T and IFNL3-G 3′ UTRs, the myomiRs were able to repress the IFNL3-T ΔARE 3′
UTR but had no significant effect on the IFNL3-G ΔARE 3′ UTR (Supplementary Fig. 3b).
Therefore, ARE-binding proteins are not physically required for miRISC recruitment to the
IFNL3-T 3′ UTR. Luciferase activity of the IFNL2 3′ UTR was also significantly reduced by
the myomiR mimics but was more resilient against low concentrations of the mimics
compared to the IFNL3 3′ UTR (Fig. 2e and Supplementary Fig. 3c). Overall these results
demonstrate that miR-208b and miR-499a-5p can directly target and mediate degradation of
the IFNL3-T 3′ UTR and that the T→G rs4803217 SNP confers protection against
repression by these myomiRs.
We found that the IFNL3 genotype of our HepG2 cell line is T/T at position rs4803217, so
we used these cells to study possible myomiR regulation of endogenous IFNL2 and IFNL3
transcripts. We treated HepG2 cells with the Toll-like receptor 3 (TLR3) ligand Poly(I:C)
and observed peak IFNL mRNA expression around 12 h post-stimulation (Supplementary
Fig. 3d). When HepG2 cells were transfected with miR-208b, miR-499a-5p or negative
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tcontrol mimics and then stimulated with Poly(I:C), we observed that both myomiRs
significantly repressed expression of IFNL2 and IFNL3 mRNA (Fig. 2f). To assess whether
this repression was a result of mRNA destabilization, we analyzed the stability of the mRNA
in the presence of the myomiR mimics following Actinomycin D treatment. To induce
IFNL, we stimulated HepG2 cells with the HCV 3′ poly U/UC tract, a pathogen-associated
molecular pattern (PAMP) of HCV encoded within the 3′ UTR that has potent
immunostimulatory effects on hepatocytes, such as inducing type I IFN33. We found that the
HCV PAMP strongly induced expression of both IFNL2 and IFNL3 in HepG2 cells
(Supplementary Fig. 3e). miR-208b, miR-499a-5p or negative control mimics as well as
HCV PAMP were transfected into HepG2 cells and 16 h post-stimulation new transcription
was arrested with Actinomycin D. We observed that miR-208b and miR-499a-5p both
reduced the IFNL2 and IFNL3 mRNA half-lives to nearly half that observed with negative
control mimics (Fig. 2g).
To support direct miRNA targeting of endogenous IFNL transcripts, we measured the
association of IFNL2 and IFNL3 mRNA with the miRISC complex. HepG2 cells were co-
transfected with either negative control mimics or a cocktail of miR-208b and miR-499a-5p
mimics along with the HCV PAMP for 16 h. We then immunoprecipitated Ago2, one of the
major miRISC proteins involved in mRNA cleavage and found significant levels of both
IFNL2 and IFNL3 mRNA within the Ago2 IP RNA of negative control mimic-treated cells,
demonstrating recruitment of miRISC by some endogenous miRNA(s) (Supplementary Fig.
3f). However, the amount of IFNL2 and IFNL3 mRNA within the Ago2 IP RNA of cells
treated with the myomiR mimics was significantly increased over the negative control
mimic-treated cells. We also amplified both miR-208b and miR-499a-5p from the Ago2-
associated RNA in the cells transfected with mimics (data not shown). Collectively, these
data confirm that miR-208b and miR-499a-5p can directly target and destabilize endogenous
IFNL2 and IFNL3 transcripts.
HCV-induced myomiRs repress IFNL3-T transcripts
To investigate the effect of endogenous HCV-induced myomiRs on the IFNL3 3′ UTR
variants, we developed reporter constructs containing either the mCherry gene or eGFP with
the IFNL3-T 3′ UTR or IFNL3-G 3′ UTR cloned downstream, respectively (Supplementary
Fig. 4a). These reporter constructs allowed for simultaneous expression of the IFNL3 3′
UTR variants within the same cells (Supplementary Fig. 4b). Flow cytometric analysis of
Huh7 cells co-transfected with these constructs showed the differential expression of IFNL3-
T versus IFNL3-G 3′ UTRs (Fig. 3a) as we had seen previously by luciferase assay (Fig.
1b). To assess whether the HCV-induced myomiRs differentially repressed the IFNL3 3′
UTR variants within the same cells, we used this mCherry/eGFP co-expression system along
with specific locked nucleic acid (LNA) inhibitors against the induced myomiRs. The LNA
inhibitors were designed to inhibit miR-208b and miR-499a-5p with high specificity, and
efficiency was demonstrated in HepG2 cells stably overexpressing miR-208b and
miR-499a-5p (Fig. 3b). To test the effect of the inhibitors on HCV-induced myomiRs, Huh7
cells were infected with HCV and then co-transfected with the mCherry/eGFP IFNL3 3′
UTR reporter constructs and LNA myomiR inhibitors or controls. Mean fluorescent
intensities were also compared to uninfected cells with the fluorescent reporters in the
McFarland et al. Page 6
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tpresence or absence of myomiR mimics. Cells infected with HCV suppressed the IFNL3-T
but not the IFNL3-G 3′ UTR reporter (Fig. 3c). The level of repression by the HCV-induced
myomiRs was similar to that observed with the mimics. Importantly, inhibition of miR-208b
and miR-499a-5p in infected cells resulted in a significant increase in IFNL3-T but not
IFNL3-G expression. Therefore, HCV infection accelerated degradation of mRNA bearing
the IFNL3-T 3′ UTR but not IFNL3-G via the induction of myomiRs.
We next determined the effect of myomiR inhibition on endogenous IFNL3 transcripts
during infection. Huh7 cells are weak producers of IFNs due to a disruption in RIG-I
helicase signaling by HCV34,35. However, IFNL2 and IFNL3 mRNA was detectable in
Huh7 cells at 72 h post-infection with a high multiplicity of infection (MOI), so we used
these conditions to study the regulation of IFNL mRNA by the myomiRs during infection
(Fig. 3d–f). Since the genotype of our Huh7 cell line was T/T at rs4803217, we could assess
the effect of the inhibitors on virally-induced IFNL3 in the presence of virally-induced
myomiRs. Induction of the myosin genes by HCV was unaffected by the presence of the
myomiR inhibitors, while myomiR expression was significantly reduced (Fig. 3d, e). We
then assayed for IFNL levels and found that the myomiR inhibitors significantly rescued
IFNL2 and IFNL3 expression over the negative control inhibitor (Fig. 3f). Furthermore,
despite the high MOI required for the expression of IFNL2 and IFNL3 in this in vitro
infection system, we were able to observe a significant decrease in viral copy number and
titer (Fig. 3g, h). These data demonstrate that HCV-induced miR-208b and miR-499a-5p
target the rs4803217 SNP in the IFNL3 3′ UTR and that myomiR inhibition can rescue this
suppression.
Induction of myosin and myomiRs during HCV infection
To investigate how HCV induces MYH7 and MYH7B, we infected Huh7.5 cells, which are
deficient in innate immune signaling by RIG-I, the essential pathogen recognition receptor
of HCV infection36,37, and measured myosin expression. Both MYH7 and MYH7B and their
respective myomiRs, miR-208b and miR-499a-5p, were induced to the levels similar to
those observed during infection of Huh7 cells (Fig. 4a, Fig. 2c, d and Supplementary Fig.
5a). We also tested for expression of the myosin genes in HepG2 cells stimulated with
Poly(I:C) or the HCV PAMP but did not observe any induction (Fig. 4b). Therefore,
induction of MYH7 and MYH7B by HCV occurs independently of HCV PAMP-RIG-I
signaling, perhaps requiring viral RNA replication or expression of HCV proteins. To test
whether the induction of the myosin genes was specific to infection with HCV, we also
assessed gene expression in Huh7 cells infected with Sendai virus (SenV) or West Nile virus
(WNV). SenV and WNV were comparatively unable to induce MYH7B and induced only
low levels of MYH7 expression, despite productive infection and induction of IFNB (Fig. 4c
and Supplementary Fig. 5b), indicating that the induction of MYH7 and MYH7B may be
HCV-specific.
Myosin and myomiRs in chronic hepatitis C patients
To determine if patients with HCV infection exhibit hepatic expression of the myosin and
their associated myomiRs, we evaluated liver RNA recovered from chronic hepatitis C
patients. Five out of 8 patients tested showed robust expression of MYH7 that was >200 fold
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tover the average uninfected control level (Fig. 5a). MYH7B was also significantly expressed
in these patients over controls (>10 fold in 5/8), albeit at a lower level than MYH7, similar to
our observation with in vitro HCV infection. Also similar to in vitro infection, we did not
detect elevated MYH6 expression, which supports a specific pathway of induction for MYH7
and MYH7B (data not shown). Hepatitis C patients also had significantly elevated hepatic
levels of miR-208b (Fig. 5a). Although these patients had elevated MYH7B expression, we
did not detect differences in mature miR-499a-5p. To examine whether this was due to
uncoupling of MYH7B expression from miR-499a-5p, we also assayed for the presence of
primary miR-499a transcripts (pri-miR-499a) and found significantly elevated levels in the
hepatitis C patients over controls. Therefore, the inability to detect mature miR-499a-5p
does not appear to be the result of an uncoupling from its parental myosin gene and may
reflect the limitation of qRT-PCR primers in detecting mature miR-499a-5p isomiRNAs in
the liver, which present obstacles for detecting mature miRNA within different tissues38,39.
However, we did observe a significant correlation between expression of MYH7 and
miR-208b as well as MYH7B with pri-miR-499a in the patients examined, demonstrating
that MYH7 mRNA levels are a reliable readout for miR-208b expression (Fig. 5b). Overall,
these observations demonstrate that HCV induces hepatic expression of cardiac and skeletal
myosin genes and associated myomiRs in infected individuals which supports the proposed
mechanism of repression of IFNL2 and IFNL3-T during infection (Supplementary Fig. 6).
DISCUSSION
The work presented here demonstrates a previously undescribed mechanism by which HCV
attenuates the hepatic innate immune IFN response. These data suggest that targeted
inhibition of miR-208b and miR-499a-5p could rescue IFNL2 and IFNL3 levels to impart
control of HCV infection. Inhibition of miR-122, which is required for HCV replication, has
recently shown promising results in clinical trials demonstrating the feasibility of anti-
miRNA therapy40. Therefore, inhibition of HCV-induced myomiRs has the potential to
become an important part of treating HCV infection and mitigating progression to cirrhosis
and liver cancer. As miR-208b and miR-499a-5p are encoded within cardiac and skeletal
muscle-specific myosin heavy chain genes, it is interesting to note that a high prevalence of
HCV infection has been reported in patients with hypertrophic cardiomyopathy, dilated
cardiomyopathy, and myocarditis41. Furthermore, autoantibodies against cardiac myosin,
including the myosin heavy chains, are commonly observed in patients with all of these
cardiac diseases42,43, suggesting that aberrant induction of cardiac myosin within the liver
by HCV may indirectly contribute to cardiac pathology.
Our comparative analysis of the IFNL2 and IFNL3 3′ UTRs revealed that despite the
significant difference in luciferase expression observed between the T and G variants of
IFNL3, the same base pair change in the IFNL2 3′ UTR did not result in an increase of
similar magnitude. If the presence of the G variant in the IFNL3 3′ UTR is the result of
genetic selection for increased IFNL3 levels during HCV infection, these data may explain
why no such variant exists for IFNL2. Namely, IFNL2 is expressed at higher levels
compared to the IFNL3-T variant and a T→G change in IFNL2 results in only a small
increase in expression. Therefore, this change in IFNL2 may not confer a host advantage
during HCV infection. Additionally, IFNL3 has been shown to have higher ISG stimulatory
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tactivity than IFNL2, which may make an IFNL3 escape variant more evolutionarily
advantageous, as it has a greater capacity to establish an antiviral state13,44.
In this study, we have identified a functional IFNL3 variant that associates with HCV
clearance. Our results reveal that the rs4803217 T→G SNP in the IFNL3 3' UTR increases
expression of IFNL3 by escaping both AMD and post-transcriptional regulation by HCV-
induced miRNAs. Between these two mechanisms of post-transcriptional regulation, IFNL3-
T suffers significantly more degradation than IFNL3-G. A frameshift variant upstream of
IFNL3 has been described that creates a novel gene, IFNL445. Expression of IFNL4 was
associated with HCV persistence and poorer response to IFN plus ribavirin therapy.
Therefore, it may be the combined effect of IFNL4 and low expression of IFNL3 that makes
this haplotype so unfavorable for HCV infection and treatment outcome. However, previous
work has shown that the IFNL genes are in low linkage disequilibrium in all populations,
suggesting that independent positive selection events are targeting these genes28. Our data
also show that HCV infection is specifically able to induce miRNAs that interact with
rs4803217 and this may explain why the IFNL3 locus has been found only to associate with
HCV and no other viral infection. Additionally, HCV genotypes may vary in their ability to
effectively induce the miRNAs which may explain why the IFNL3 GWAS SNPs do not
uniformly associate with response to therapy across infections with all HCV genotypes.
Thus, the identification of this causal IFNL3 3′ UTR SNP provides a potentially important
link between host and HCV genetics.
ONLINE METHODS
Cell lines and culture conditions
HepG2, Huh7 or Huh7.5 cells were grown in DMEM (Sigma) medium with 10% heat-
inactivated fetal bovine serum (FBS; Atlanta Biologicals) and 1% penicillin-streptomycin-
glutamine (Mediatech) at 37°C in 5% CO2.
Genotype analysis of rs4803217
The IFNL3 locus, including the 3′ UTR, was amplified from genomic DNA extracted from
HepG2 or Huh7 cells using the following primer pair: forward 5′-gagcaggtggaatcctcttg-3′
and reverse 5′-agcaggcaccttgaaatgtc-3′. The PCR product was then genotyped at rs4803217
according to the ABI TaqMan genotyping assay procedure with the following primer pair
and probes: forward primer 5′-gccagtcatgcaacctgagatttta-3′ and reverse primer 5′-
aaatacataaatagcgactgggtgaca-3′; probe for IFNL3-T 5′-FAM-ttagccacttgtcttaat-NFQMGB-3′
and probe for IFNL3-G 5′-VIC-tagccacttggcttaat-NFQMGB-3′.
Secondary structure prediction
Per-residue base pair probabilities of IFNL3-T and IFNL3-G were computed as a column-
wise sum of the predicted base probability matrix using the RNAfold program (Vienna RNA
package, version 2.0.0, using option “-p”)46.
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Full-length 3′ UTRs (Supplementary Fig. 1a) for human IFNL2 (containing either a T or G
at 3′ UTR position 53) and IFNL3 (containing either a T or G at SNP rs4803217) were
cloned in an XbaI site downstream of the luciferase gene in the pGL3 reporter vector
(Promega). IFNL2 and IFNL3-T 3′ UTR luciferase constructs containing disrupted AREs
were created by introducing a C instead of a T nucleotide (ATTTA→ATCTA) in all three
ATTTA motifs (synthesized by Life Technologies). IFNL3-T 3′ UTRs with individual ARE
sites disrupted were synthesized and subcloned into the pGL3 vector. The following
primers: forward 5′-tttatctataaattagccac ttgtcttaatctattgtcacccagtcg-3′ and reverse 5′-
cgactgggtgacaatagattaagacaagtggctaatttatagataaa-3′ were used to introduce by site-directed
mutagenesis (Stratagene) a T→G at position 53 in the IFNL3-G ∆ARE and individual
mutant ARE constructs.
miRNA-target pairing site prediction
Bioinformatic analysis using RNAhybrid (version 2.2) revealed a potential miRNA binding
site for the myomiR family members miR-208b and miR-499a-5p at rs4803217 in the
IFNL3-T and IFNL2 3′ UTRs. Nucleotide positions 43 to 59 in the IFNL3-T 3′ UTR were
predicted to pair with these myomiRs.
Cell transfections and reporter assays
For luciferase assays, HepG2 or Huh7 cells were plated at a density of 1×104 cells/well in a
96-well plate and grown overnight. Cells were transfected with 20–40 ng/well of pGL3 and
0.1–0.5 ng/well of Renilla reporter constructs with 0.2µl/well of X-tremeGENE 9 DNA
transfection reagent (Roche). Co-transfection experiments with 20 nM of myomiR mimics
(miR-208b and miR-499a-5p; Dharmacon) were conducted with 0.1–0.2 µl/well of
DharmaFECT Duo transfection reagent (Dharmacon). A negative control (NC) mimic that
does not bind to any target in mammalian genes (Dharmacon) was included in all
experiments as necessary. After 48 h of incubation, the cells were lysed and the firefly and
Renilla luciferase activities were measured with the Dual-Luciferase Reporter Assay System
(Promega) using a multi-mode microplate reader (Synergy HT, BioTek). Luciferase activity
is plotted as percent ratio of Luciferase/Renilla. For co-expression experiments using
mCherry and eGFP reporter constructs, Huh7 cells (either HCV-infected or uninfected) were
transfected using 1 µl/well in a 48-well plate of DharmaFECT Duo transfection reagent with
50 ng of total plasmid (controls and IFNL3 3′ UTR reporters were mixed in a 1:1 ratio)
along with 40 nM of a cocktail of locked nucleic acid inhibitors (LNA) against miR-208b
and miR-499a-5p (designed with Exiqon). The negative control inhibitor was an LNA
mismatched against miR-208b and miR-499a-5p. For studies on the endogenous regulation
of IFNL2 and IFNL3 mRNA by HCV-induced myomiRs, Huh7 cells were plated at a
density of 3×105 cells/well in 2 ml of a 6-well plate and 8 h later transfected with 40 nM of
inhibitors (myomiRs or NC). 16 h post-transfection, cells were washed and replated into 12-
well dishes at a density of 1×105 cells/well and infected with HCV after 6 h.
To study the effect of miR-208b and miR-499a-5p on endogenous IFNL2 and IFNL3
expression, HepG2 cells were plated at a density of 3×105 cells/well in a 6-well plate in 2 ml
and grown overnight. 20 nM of mimics were transfected with 5 µl of DharmaFECT 4
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ttransfection reagent per well. After 24 h of incubation, cells were transfected/stimulated
with 3 µg/well of Poly(I:C) (InvivoGen) using 3 µl/well of X-tremeGENE 9 transfection
reagent according to the manufacturer’s instructions (Roche). For experiments involving the
HCV 3′ poly U/UC PAMP33,47, 20 nM of mimics were co-transfected with 100 or 500 ng of
the PAMP into HepG2 cells using 3 µl of DharmaFECT Duo transfection reagent per well.
pLV-miRNA overexpressing lines
Lentiviral vectors producing miR-208b or miR-499a-5p were transduced into HepG2 cells
by lentiviral infection as previously described48. Briefly, self-inactivating pLV-miR-208b,
pLV-miR-499a-5p or pLV-control (Biosettia) were used to generate vesicular stomatitis
virus-pseudotyped lentiviral vectors. pLV constructs were transfected into HEK293FT cells
using FuGENE 6 (Roche) according to the manufacturer’s instruction. HepG2 cells were
transduced by lentivirus. Post-transduction the cells were selected with 5 µg/ml puromycin
(Sigma-Aldrich). The levels of miRNA expression were evaluated by real-time PCR probing
for mature miR-208b and miR-499-5p.
RNA and miRNA expression analysis by RT-PCR
RNA was extracted using the RNeasy Kit (Qiagen) and reverse transcribed using the
QuantiTect RT kit (Qiagen). RT-PCR primers/probe previously designed and tested for
specificity were used to detect IFNL2 and IFNL321: 900 nM IFNL2 forward (5′-
gaaggttctggaggccacc-3′) and 900 nM IFNL2 reverse (5′-ggctggtccaagacgtcca-3′); 900 nM
IFNL3 forward 5′-gaaggttctggaggccacc-3′ and 900 nM IFNL3 reverse 5′-
ggctggtccaagacatcc-3′; 250 nM probe 5′FAM-gctgacactgacccagccctgg-TAMRA-3′. Relative
quantification of human IFNB1, MYH6, MYH7, MYH7B and pri-miR-499a was performed
using TaqMan RT-PCR assays (Life Technologies). HPRT and GAPDH (Integrated DNA
Technologies) were used as endogenous controls.
miRNA was extracted using Trizol (Invitrogen). Relative quantification of mature hsa-
miR-208b and hsa-miR-499a-5p was performed using miRCURY LNA Universal RT
microRNA PCR assays according to the manufacturer’s instructions (Exiqon). Among the
commercially available microRNA primers, we found the Exiqon LNA primers for
miR-208b and miR-499a-5p to have superior efficiency. Three Exiqon LNA primers
designed to detect the most common mature miR-499a-5p isomiRNAs (miRBase) were
pooled for detection. The miR-208b Exiqon LNA primer was optimized by using primers
with lower Tm. SNORD38B was used as an endogenous control. mRNA stability
experiments were performed using 10 µg of Actinomycin D (Act D) per 1×106 cells/ml. For
stability of the firefly luciferase mRNA, total RNA was extracted (Qiagen) and
polyadenylated mRNA was purified from the preparation using a Dynabead mRNA
Purification Kit (Ambion/Life Technologies). Firefly luciferase mRNA was detected using
custom designed TaqMan primers (Life Technologies). No RT controls were included and
showed no amplification.
Flow cytometry
Flow cytometry was performed on Huh7 cells using an LSRII (BD Biosciences). For all
experiments, cells were fixed in 3% paraformaldehyde in 1× PBS for 30 min.
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mRNA:miRNA-protein complexes were immunoprecipitated (IP) as previously described49.
Briefly, 3×106 HepG2 cells were plated in 10 cm2 dishes and grown overnight. Each plate
was co-transfected with 20 nM of NC mimics or a cocktail of miR-208b and miR-499a-5p
as well as 2 µg HCV PAMP using 5 µl DharmaFECT Duo transfection reagent. At 16 h
post-transfection the cells were lysed in polysome lysis buffer. An aliquot of the lysate was
taken to obtain the input HPRT mRNA values for normalization. Lysates were precleared
for 1 h with protein G beads (GE Healthcare 17-0618-02) followed by overnight IP with 10
µg of control IgG or anti-Ago2 antibody (Wako 015-22031) conjugated to protein G beads.
IPs were washed with polysome lysis buffers and aliquots were taken for Western blot
analysis of Ago2 and for RNA detection of IFNL2, IFNL3, miR-208b and miR-499a-5p.
Virus infection of Huh7 and Huh7.5 cell lines
Cell culture adapted HCV JFH1 genotype 2A strain was propagated and infectivity titrated
by focus forming assay, as previously described50. For HCV infection experiments, cells
were inoculated with virus (MOI 0.3 or MOI 10 where indicated) for 3 h and then the media
was replaced. Cells were harvested with Trizol at the indicated times. HCV RNA copy
number was measured by quantitative real-time PCR using the TaqMan Fast Virus 1-step kit
and primers specific for the 5′UTR (Pa03453408_s1, Life Technologies). The copy number
was calculated by comparison to a standard curve of in vitro transcribed full-length HCV
RNA. Sendai virus strain Cantell was obtained from Charles River Laboratory. West Nile
virus (TX strain51) stocks were generated by a single round of amplification on Vero-E6
(ccl-81; ATCC) cells and supernatants were collected, aliquoted, and stored at −80°C. Virus
stocks were titered by a standard plaque assay on BHK21 cells as previously described52.
Liver biospecimens
Liver tissue of chronic hepatitis C infected or control livers were obtained with the approval
of the university Institutional Review Board, and the participants provided written informed
consent approved by our ethics committee. Unused samples from percutaneous biopsies of
patients with chronic hepatitis C with no pathological evidence of fibrosis (mild HCV;
Metavir grade 1, stage 0) were analyzed (n=8). Control liver tissue was obtained from
unused donor liver (n=6) with IRB approval. All liver samples were flash frozen in liquid
nitrogen upon collection and stored at −80°C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
IFNL3 rs4803217 3′ UTR variants are differentially regulated and are subject to ARE-
mediated decay. (a) Alignment of IFNL3-T and IFNL3-G 3′ UTR sequences (nt 40 to 70).
SNP rs4803217 at nt position 53 is indicated with an arrow. (b) HepG2 or Huh7 cells were
transfected with the indicated constructs. Data are plotted as the percent Luciferase/Renilla
ratio compared to the mean activity of the control construct. (c) IFNL3-T or IFNL3-G
luciferase constructs were transfected into HepG2 cells and treated with Act D to arrest new
transcription. Stability was determined as percent luciferase mRNA remaining over time,
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tcompared to 0 h. Half-life (t1/2) of luciferase mRNA bearing the IFNL3-G 3′ UTR was 7.0 h
(R2 = 0.82) compared to 3.3 h for the luciferase mRNA bearing the IFNL3-T 3′ UTR (R2 =
0.95). Data represent mean ± s.e.m. from one of three comparable experiments. (d)
Alignment of IFNL3 3′ UTR sequences (nt 30 to 90) showing AU-rich elements (ARE 1–3,
boxed) and mutations introduced to disrupt the motifs (ΔARE, ATTTA→ATCTA). (e–g)
HepG2 cells were transfected with the indicated constructs. Data are plotted as the percent
Luciferase/Renilla ratio compared to the activity of the control construct. (f) Data are plotted
as the percent degradation compared to the luciferase activity of the control construct (set at
0%). (b, e-g) Data represent six replicates in each experimental group plotted as mean ±
s.e.m. from one representative of three or more experiments. Unpaired t tests (e, g) or two-
way analysis of variance (f) were used for statistical comparisons and two-tailed P values
are given. *P<0.05, **P≤0.0005.
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tFigure 2.
Variation in the IFNL3 3′ UTR mediates post-transcriptional repression by HCV-induced
myomiRs, miR-208b and miR-499a-5p. (a) RNAhybrid analysis was used to show the
miRNA:target interaction for hsa-miR-208b and hsa-miR-499a-5p which bind at nucleotide
positions 43 to 58 of the IFNL3-T and IFNL2 3′ UTRs. The rs4803217 T→G SNP
(underlined) is located at nucleotide position 53 in the mRNA. (b) Schematic showing the
chromosomal location of the human MYH7 and MYH7B genes (grey arrows) and the intronic
miRNAs, MIR208B and MIR499A (black arrows), that they encode. (c, d) Huh7 cells were
infected with HCV for 24, 48 and 72 h and expression of MYH7, MYH7B, miR-208b and
miR-499a-5p was assessed. Reference sample for relative quantification was mock infected
cells taken at 48 h. Data represent mean ± s.e.m. of four individual experiments pooled.
One-way analysis of variance was used for statistical comparisons across the time points
compared to the mock (M) infection. (e) HepG2 cells were co-transfected with the indicated
IFNL 3′ UTR luciferase reporter constructs along with the indicated mimics (NC, negative
control). Data are plotted as the percent Luciferase/Renilla ratio compared to the mean
activity of each construct co-transfected with NC mimics. Data represent six replicates in
each experimental group plotted as mean ± s.e.m. from one representative of three
experiments. Unpaired t tests were used for statistical comparisons and two-tailed P values
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tare given. (f) HepG2 cells were transfected with the indicated mimics and then stimulated
with Poly(I:C). IFNL2 and IFNL3 mRNA levels were assessed and are plotted as percent
expression compared to cells transfected with NC mimics. Data represent mean ± s.e.m. and
are pooled from three individual experiments. Unpaired t tests were used for statistical
comparisons and two-tailed P values are given. (g) HepG2 cells were co-transfected with
HCV PAMP and the indicated mimics. Act D was added 16 h post-transfection and the
percent of IFNL2 (T/T) and IFNL3 (T/T) mRNA remaining over time was assessed. All
curve fits for IFNL2 and IFNL3 mRNA degradation over time had R2 ≥ 0.85. Comparison of
Fits showed differences in IFNL2 and IFNL3 mRNA stability were significantly different
(P<0.0001 and P=0.0005, respectively). The mRNA half-lives (50% mRNA remaining, t1/2)
for the IFNL2 mRNA were NC t1/2 = 4.5 h, miR-208b t1/2 = 2.4 h, miR-499a-5p t1/2 = 2.7 h
and for IFNL3 mRNA were NC t1/2 = 5.4 h, miR-208b t1/2 = 3.1 h, miR-499a-5 t1/2 = 3.2 h.
Data represent mean ± s.e.m. and one of two comparable experiments performed is shown.
*P<0.05, **P<0.01, ***P<0.001.
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Inhibition of HCV-induced myomiRs increases IFNL2 and IFNL3 expression as well as the
antiviral response. (a) Mixes of mCherry and eGFP control 3′ UTR reporters or mCherry-
IFNL3-T and eGFP-IFNL3-G 3′ UTR reporters were co-transfected into Huh7 cells and
fluorescence was analyzed by flow cytometry after 48 h. Shown are histogram plots of
IFNL3-T and IFNL3-G expression versus their controls. (b) To test the efficiency of LNA
inhibitors designed against miR-208b and miR-499a-5p, HepG2 cells stably expressing
miR-208b or miR-499a-5p were transfected with the inhibitors and miRNA expression was
measured by RT-PCR. Efficiency of inhibition was >75% with 40 nM of inhibitors 48 h
post-transfection. (c) HCV-infected Huh7 cells were co-transfected with mixes of the
reporter constructs (either controls or IFNL3 3′ UTRs) shown in (a) and after 48 h the mean
fluorescent intensities (MFI) were determined. Data is normalized to MFIs of the 3′ UTR
control reporters and then plotted as relative expression to IFNL3-G treated with NC. (d–h)
The myomiR inhibitors were transfected into Huh7 cells 24 h prior to infection with HCV.
Expression analysis of MYH7 and MYH7B (d), miR-208b and miR-499a-5p (e), IFNL2 and
IFNL3 (f), and quantification of HCV viral copy number and titer (g and h) was carried out
72 h post-infection. Reference sample for relative quantification was mock infected cells.
(b–h) Data represent mean ± s.e.m. and one of three comparable experiments performed is
shown. Unpaired t tests were used for statistical comparisons and two-tailed P values are
given. *P<0.05, **P<0.01, ***P<0.001.
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Induction of MYH7 and MYH7B is HCV infection-specific. (a) Huh7.5 cells were infected
with HCV for 24 and 48 h and expression of MYH7, MYH7B, miR-208b and miR-499a-5p
was assessed. Reference sample for relative quantification was mock (M) infected cells
taken at 48 h. Data represent mean ± s.e.m. and one of three comparable experiments
performed is shown. One-way analysis of variance was used for statistical comparisons
across the time points compared to the mock infection. (b) HepG2 cells were stimulated
with Poly(I:C) or HCV PAMP for the indicated times. Expression of IFNL3, IFNB, MYH7
and MYH7B was assessed compared to unstimulated cells. (c) Huh7 cells were infected with
HCV, Sendai virus (SenV) or West Nile virus (WNV) for 24, 48 and 72 h. Expression of
MYH7 and MYH7B was assessed across the infections. Data represent mean ± s.e.m. and one
of two comparable experiments performed is shown. Two-way analysis of variance was
used for statistical comparisons. *P<0.05, **P<0.01, ***P<0.001.
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Expression of myosin and myomiRs in chronic hepatitis C patients. (a) RNA isolated from
the livers of chronic hepatitis C patients (n=8) or controls (n=6) was tested for MYH7,
MYH7B, miR-208b, miR-499a-5p and pri-miR-499a-5p expression. Non-parametric Mann
Whitney tests were used for statistical comparisons and two-tailed P values are indicated.
NS, not significant, *P=0.02, **P<0.005. (b) Correlation between MYH7 vs. miR-208b
expression (Pearson’s r, P=0.0014) and MYH7B vs. pri-miR-499a-5p expression (Pearson’s
r, P=0.0033) in hepatitis C patients. R2 values from nonlinear regressions are indicated.
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